Medintek
General Information  
 

 

  The Proven Performance of the S-Stent Platform on a new generation delivery system

that provides great trackability for tortuous vessels and crossability for tight lesions

Key Features and Benefists

Open cell design with Quadrature Link™

Excellent side branch Access

Excellent flexibility

Low stent profile

Good crossability

New hydrophilic coating

Upgraded balloon material

High deliverability

Gazelle provides:

  • Greater trackability for tortuous vessels

  • Excellent crossability for tight lesions

Tiger™ Stent Delivery System

Key features and benefists

Soft and multiple folding balloon material maintains low stent profile and ensures uniform expansion

Enhanced crossability trackability

Slip-X hydrophilic coating

Enhanced tracability through tortuous vessels

Swaged markers

Improved stent placement visibility

Tapered Power Stylet design

Excellent kink resistance

Clinical evidence

S-Stent Multicenter Safety And Efficacy Trial

Prospective multicenter feasibilty study performed in 4 centres, N=120

Primary Endpoint: MACE at 30 days.

Secondary Endpoint: Acute and long term angiographic outcome after Biosensors S-Stent implantation.

Results:

MACE at 6 months: 1,68%

Angiographic restenosis rate at 6 months: 16,5%

TLR at 6 monhts: 10%

Stent deployment was successful in 100% of lesions.

Coclusion:

The S-Stent has uniform expanding property and excellent deliverability.


S-Stent Japan Clinical Trial

A non-randomized prospective study.

N=105.

Primary EndPoint: 6 monhts QCA, 6 months Binary Restenosis, 6 months MACE.

Results:

MACE at 30 days: 0,0%

MACE at 6 months:5,7%

Binary Restenosis at 6 months: 10,9%

QCA at 6 months: 29,5%

Conclusion:

Safety and efficacy of S-Stent demonstrated at 6 months.

   
Ürünler Ana Sayfasına Dön

Medintek Medical Ltd . Reşit Galip Cad. Han sokak 13/1 G.O.P / ANKARA TURKEY Tel: +90 (312) 437 76 86 Fax: +90 (312) 437 47 97 e-mail: info@medintek.com.tr
Copyright © 2008, Medintek Medikal | Design: İNAJANS